News Gilead, Amgen kick off facility investments in US This week saw both Gilead Sciences and Amgen start to fulfil pledges to step up capital investments in new US facilities.
News Gilead poised to bring twice-yearly HIV PrEP to EU Gilead gets EU approval for its twice-yearly PrEP product Yeytuo, another key step in building what it hopes will be a new HIV blockbuster.
News Gilead buys in vivo cell therapy firm Interius for $350m Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.
News Lilly's appeal unlocks EU approval of Alzheimer's drug Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.
News Gilead's twice-yearly HIV PrEP set for wider rollout The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.
News Kymera signs $750m cancer deal with Gilead as Sanofi opts in Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another.
News Moderna jab on trial for cancer-causing syndrome Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
